Literature DB >> 19793347

Carcinogenic potential of alizarin and rubiadin, components of madder color, in a rat medium-term multi-organ bioassay.

Kaoru Inoue1, Midori Yoshida, Miwa Takahashi, Hitoshi Fujimoto, Makoto Shibutani, Masao Hirose, Akiyoshi Nishikawa.   

Abstract

Madder color (MC), a food coloring extracted from roots of Rubia tinctorum L., has been proven to exert carcinogenicity in the rat kidney and liver. Furthermore, it induces DNA adducts in the kidney, liver, and colon. MC is in fact composed of anthraquinones such as lucidin-3-O-primeveroside and alizarin. To clarify which of these might be responsible for the carcinogenicity, a rat medium-term multi-organ carcinogenesis bioassay was performed focusing on the kidney, liver, and colon. Male 6-week-old F344 rats after receiving five different carcinogens were fed a diet containing either 0.008% or 0.04% of alizarin or rubiadin, a metabolite of lucidin-3-O-primeveroside, for 23 weeks. Treatment with 0.04% rubiadin significantly increased atypical renal tubules/hyperplasias and induced renal cell adenomas and carcinomas. Renal cell tumors were also increased with 0.04% alizarin, although at lower incidence than with rubiadin. In addition, glutathione S-transferase placental form-positive liver cell foci and large intestinal dysplasias were significantly increased with 0.04% rubiadin. These results indicate that both rubiadin and alizarin can increase renal preneoplastic lesions, the potential of the latter being weaker. Rubiadin may also target the liver and large intestine, suggesting a major role in madder color-induced carcinogenicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793347     DOI: 10.1111/j.1349-7006.2009.01342.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Genotoxicity Comparison between Morinda citrifolia Fruit and Seed Substances.

Authors:  Sarah Shin; Ji Soo Kim; Myung Ku Park; Ok-Sun Bang
Journal:  Foods       Date:  2022-06-16

2.  Targeted tumor therapy by Rubia tinctorum L.: analytical characterization of hydroxyanthraquinones and investigation of their selective cytotoxic, adhesion and migration modulator effects on melanoma cell lines (A2058 and HT168-M1).

Authors:  Eszter Lajkó; Péter Bányai; Zsófia Zámbó; László Kursinszki; Éva Szőke; László Kőhidai
Journal:  Cancer Cell Int       Date:  2015-12-18       Impact factor: 5.722

Review 3.  Morinda citrifolia Linn. (Noni) and Its Potential in Obesity-Related Metabolic Dysfunction.

Authors:  Aline Carla Inada; Priscila Silva Figueiredo; Rosângela Aparecida Dos Santos-Eichler; Karine de Cássia Freitas; Priscila Aiko Hiane; Alinne Pereira de Castro; Rita de Cássia Avellaneda Guimarães
Journal:  Nutrients       Date:  2017-05-25       Impact factor: 5.717

Review 4.  Chemistry, Biosynthesis, Physicochemical and Biological Properties of Rubiadin: A Promising Natural Anthraquinone for New Drug Discovery and Development.

Authors:  Mohd Nasarudin Watroly; Mahendran Sekar; Shivkanya Fuloria; Siew Hua Gan; Srikanth Jeyabalan; Yuan Seng Wu; Vetriselvan Subramaniyan; Kathiresan V Sathasivam; Subban Ravi; Nur Najihah Izzati Mat Rani; Pei Teng Lum; Jaishree Vaijanathappa; Dhanalekshmi Unnikrishnan Meenakshi; Shankar Mani; Neeraj Kumar Fuloria
Journal:  Drug Des Devel Ther       Date:  2021-11-03       Impact factor: 4.162

Review 5.  A comprehensive review of Rubia cordifolia L.: Traditional uses, phytochemistry, pharmacological activities, and clinical applications.

Authors:  Min Wen; Qi Chen; Wang Chen; Jing Yang; Xiaogang Zhou; Chunxiang Zhang; Anguo Wu; Jia Lai; Jianping Chen; Qibing Mei; Shuo Yang; Cai Lan; Jianming Wu; Feihong Huang; Long Wang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

6.  Anthraquinone Content in Noni (Morinda citrifolia L.).

Authors:  Rainer W Bussmann; Lothar Hennig; Athanassios Giannis; Jutta Ortwein; Toni M Kutchan; Xi Feng
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-26       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.